Pediatric Hematology & Oncology at Fudan University Children's Hospital Shanghai | CMCS

Expert Childhood Cancer & Blood Disease Care at China's Premier Children's Hospital

The Department of Hematology and Oncology at Fudan University Children's Hospital (FUCH) — also known as Children's Hospital of Fudan University — is one of China's most distinguished centers for the diagnosis and treatment of childhood cancers and blood diseases, with a national reputation for excellence in pediatric leukemia, lymphoma, solid tumors, bone marrow transplantation, and CAR-T cell therapy. As one of China's highest-volume pediatric hematology-oncology programs, the department combines outstanding clinical expertise with a world-class research program and a fully integrated multidisciplinary approach, offering international families access to the latest evidence-based treatments and clinical trials for childhood cancers.

For international families with a child diagnosed with leukemia, lymphoma, a solid tumor, or a serious blood disease — whether seeking treatment, a second opinion, access to CAR-T cell therapy, or expert management of a relapsed or refractory cancer — FUCH's hematology and oncology department offers an unparalleled combination of pediatric oncological expertise and research leadership. China Medical Concierge Shanghai (CMCS) provides seamless end-to-end coordination for international families throughout their child's care journey at FUCH.

About the Department

FUCH's hematology and oncology department is a national key clinical specialty operating dedicated pediatric hematology-oncology inpatient wards, a bone marrow transplantation unit (BMT), a CAR-T cell therapy program, a comprehensive outpatient hematology-oncology clinic, a pediatric oncology MDT, and works in close collaboration with pediatric surgery, radiation oncology, pathology, and molecular diagnostics through a fully integrated multidisciplinary team.

The department's bone marrow transplantation program is one of the most experienced in China for pediatric patients, performing allogeneic and autologous transplants for leukemia, lymphoma, and non-malignant hematological conditions. The CAR-T cell therapy program offers chimeric antigen receptor T-cell therapy for relapsed/refractory B-cell ALL and other hematological malignancies, representing one of the most advanced cellular therapy programs available for children in China. Faculty members publish regularly in leading pediatric oncology journals including Journal of Clinical Oncology, Blood, Leukemia, Pediatric Blood & Cancer, and British Journal of Haematology.

Conditions Treated

Pediatric Leukemia

• Acute Lymphoblastic Leukemia (ALL) — Risk-stratified treatment with CCLG-ALL or COG-ALL protocols; standard, high, and very high-risk ALL; CNS-directed therapy; MRD-guided treatment intensification; blinatumomab for MRD-positive ALL; inotuzumab ozogamicin for relapsed B-ALL; nelarabine for T-ALL; allogeneic BMT for very high-risk and relapsed ALL
• Philadelphia Chromosome-Positive ALL (Ph+ ALL) — Tyrosine kinase inhibitors (imatinib, dasatinib, ponatinib) combined with chemotherapy; allogeneic BMT in first remission
• Philadelphia-Like ALL (Ph-like ALL) — Genomic profiling for ABL-class fusions and JAK-STAT pathway alterations; targeted therapy with TKIs or ruxolitinib
• Acute Myeloid Leukemia (AML) — AML-BFM or CCLG-AML protocols; FLT3 inhibitors (midostaurin, gilteritinib) for FLT3-ITD AML; gemtuzumab ozogamicin for CD33-positive AML; allogeneic BMT for high-risk AML
• Acute Promyelocytic Leukemia (APL) — ATRA + arsenic trioxide; excellent cure rates with minimal chemotherapy
• Chronic Myeloid Leukemia (CML) — Imatinib, dasatinib, and nilotinib; treatment-free remission for selected patients
• Juvenile Myelomonocytic Leukemia (JMML) — Allogeneic BMT as definitive treatment; RAS pathway mutation-guided management
• Relapsed/Refractory ALL — Blinatumomab; inotuzumab ozogamicin; CAR-T cell therapy (tisagenlecleucel/axi-cel); salvage chemotherapy; allogeneic BMT

Pediatric Lymphoma

• Hodgkin Lymphoma — Risk-adapted ABVD or BEACOPP-based protocols; brentuximab vedotin for relapsed/refractory HL; pembrolizumab and nivolumab for PD-L1-positive HL; autologous BMT for relapsed disease
• Diffuse Large B-Cell Lymphoma (DLBCL) — R-CHOP; CAR-T cell therapy (axicabtagene ciloleucel, tisagenlecleucel) for relapsed/refractory DLBCL; polatuzumab vedotin + BR
• Burkitt Lymphoma — Intensive short-course chemotherapy (LMB/BFM protocols); rituximab; excellent cure rates with modern therapy
• Anaplastic Large Cell Lymphoma (ALCL) — ALCL99 protocol; brentuximab vedotin for ALK-positive ALCL; crizotinib for ALK-positive relapsed ALCL
• T-Cell Lymphoma — Chemotherapy; romidepsin and pralatrexate for relapsed disease
• Lymphoblastic Lymphoma — ALL-type protocols; allogeneic BMT for high-risk disease

Pediatric Solid Tumors

• Wilms Tumor (Nephroblastoma) — Nephrectomy and chemotherapy (actinomycin D + vincristine ± doxorubicin); bilateral Wilms tumor management; WT1 and CTNNB1 mutation-guided therapy
• Neuroblastoma — Risk-stratified treatment; high-risk neuroblastoma: induction chemotherapy, surgery, high-dose chemotherapy with autologous BMT, radiation, dinutuximab immunotherapy, isotretinoin maintenance; DFMO for maintenance; ALK inhibitors (crizotinib, lorlatinib) for ALK-mutated neuroblastoma
• Medulloblastoma — Surgical resection, craniospinal irradiation (proton therapy preferred), and chemotherapy; molecular subgroup-guided therapy (WNT, SHH, Group 3, Group 4); vismodegib for SHH-activated medulloblastoma
• Ependymoma — Surgical resection and focal radiation; molecular subgroup-guided therapy
• Pediatric High-Grade Glioma — Surgical resection, radiation, and temozolomide; BRAF V600E inhibitors (dabrafenib + trametinib) for BRAF-mutated pediatric HGG; H3 K27M-mutated DIPG: ONC201 and clinical trials
• Pediatric Low-Grade Glioma — BRAF inhibitors (dabrafenib + trametinib, tovorafenib) for BRAF-altered LGG; MEK inhibitors (selumetinib) for NF1-associated LGG; surgical resection for accessible tumors
• Rhabdomyosarcoma — Risk-stratified multimodality treatment; surgery, chemotherapy (VAC/VI), and radiation; proton therapy for head and neck and pelvic RMS
• Ewing Sarcoma — VDC/IE chemotherapy; surgical resection and/or radiation; high-dose chemotherapy with autologous BMT for high-risk disease
• Osteosarcoma — MAP chemotherapy (methotrexate, doxorubicin, cisplatin); limb-salvage surgery; mifamurtide for non-metastatic osteosarcoma
• Hepatoblastoma — PRETEXT staging; cisplatin-based chemotherapy; surgical resection; liver transplantation for unresectable disease
• Retinoblastoma — Intra-arterial chemotherapy; intravitreal chemotherapy; systemic chemotherapy; laser and cryotherapy; enucleation; genetic counseling for heritable RB1 mutations
• Germ Cell Tumors — BEP chemotherapy; surgical resection; fertility preservation

Non-Malignant Hematological Conditions

• Aplastic Anemia — Allogeneic BMT for severe AA; horse ATG + cyclosporine for non-transplant candidates; eltrombopag; luspatercept
• Thalassemia — Allogeneic BMT for transfusion-dependent thalassemia; luspatercept for non-transfusion-dependent thalassemia; gene therapy clinical trials
• Sickle Cell Disease — Allogeneic BMT; hydroxyurea; voxelotor; crizanlizumab; gene therapy
• Hemophilia — Factor replacement therapy; emicizumab for hemophilia A; gene therapy clinical trials
• Immune Thrombocytopenia (ITP) — Corticosteroids; IVIG; rituximab; TPO receptor agonists (eltrombopag, romiplostim)
• Hemophagocytic Lymphohistiocytosis (HLH) — HLH-2004 protocol; emapalumab for refractory primary HLH; allogeneic BMT for primary HLH
• Primary Immunodeficiency Diseases — SCID, WAS, CGD, and other PIDs; allogeneic BMT; gene therapy

CAR-T Cell Therapy Program

FUCH's CAR-T cell therapy program is one of the most advanced pediatric cellular therapy programs in China, offering chimeric antigen receptor T-cell therapy for children with relapsed or refractory hematological malignancies:

• Tisagenlecleucel (Kymriah) — CD19-targeted CAR-T for relapsed/refractory B-cell ALL in patients up to 25 years; one of China's most experienced pediatric tisagenlecleucel programs
• CD19 CAR-T for DLBCL — Axicabtagene ciloleucel and lisocabtagene maraleucel for relapsed/refractory DLBCL
• CD22 CAR-T — For CD19-negative relapsed ALL after prior CD19 CAR-T; investigational
• Bispecific CAR-T (CD19/CD22) — Investigational dual-targeting CAR-T to reduce antigen escape
• CAR-T for Solid Tumors — GD2-targeting CAR-T for neuroblastoma and osteosarcoma; investigational clinical trials

Bone Marrow Transplantation Program

FUCH's BMT program is one of the most experienced pediatric transplant programs in China:

• Allogeneic BMT — Matched sibling donor, matched unrelated donor, haploidentical (parent) donor, and umbilical cord blood transplantation; Beijing Protocol for haploidentical transplantation
• Autologous BMT — High-dose chemotherapy with autologous stem cell rescue for neuroblastoma, Ewing sarcoma, and relapsed lymphoma
• Reduced-Intensity Conditioning — For patients unable to tolerate myeloablative conditioning; non-malignant conditions
• GvHD Prevention & Management — Post-transplant cyclophosphamide (PTCy); ruxolitinib for steroid-refractory acute and chronic GvHD; belumosudil for chronic GvHD

Why International Families Choose FUCH Hematology & Oncology

• Pediatric Specialization — Dedicated children's hospital with all care optimized for pediatric patients and families
• CAR-T Cell Therapy — One of China's most experienced pediatric CAR-T programs for relapsed/refractory ALL and lymphoma
• High-Volume BMT Program — Extensive experience with haploidentical, matched unrelated, and cord blood transplantation for children
• Molecular Precision Oncology — Ph-like ALL genomic profiling, BRAF/ALK-targeted therapy for pediatric brain tumors and solid tumors
• Clinical Trial Access — Active participation in national and international pediatric oncology trials
• Cost-Effectiveness — World-class pediatric cancer care at significantly lower cost than equivalent treatment in Western countries

The CMCS Patient Journey

1. Initial Inquiry — Share your child's diagnosis, pathology reports, bone marrow biopsy results, molecular profiling, imaging, and prior treatment history with CMCS.
2. Medical Record Preparation — We translate and organize your child's records for specialist pre-consultation review.
3. Specialist Matching — We identify the most appropriate pediatric hematologist-oncologist based on your child's diagnosis — leukemia, lymphoma, solid tumor, or non-malignant blood disease.
4. MDT Submission — Where appropriate, we facilitate pre-arrival case review by FUCH's pediatric oncology MDT.
5. Priority Scheduling — We secure a consultation with minimal waiting time.
6. Travel & Logistics — Assistance with visa invitation letters, family accommodation near FUCH, and Shanghai airport transfers.
7. Treatment Coordination — Full coordination of bone marrow biopsy, molecular profiling, chemotherapy scheduling, BMT admission, or CAR-T cell therapy enrollment.
8. Post-Treatment Follow-Up — Treatment summary translation, maintenance therapy guidance, and remote follow-up coordination after you return home.

Book a Consultation

If your child has been diagnosed with leukemia, lymphoma, a solid tumor, or a serious blood disease and you are seeking expert pediatric hematology-oncology care in Shanghai — including CAR-T cell therapy or bone marrow transplantation — CMCS can arrange a specialist consultation with FUCH's pediatric hematology and oncology team.

📧 contract@medicalsh.com
💬 WhatsApp: https://wa.me/message/3AM6KAGCW2BAD1
🌐 www.medicalsh.com